Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Solid Biosciences (SLDB) Shares Outstanding (Weighted Average): 2017-2024

Historic Shares Outstanding (Weighted Average) for Solid Biosciences (SLDB) over the last 7 years, with Dec 2024 value amounting to $40.0 million.

  • Solid Biosciences' Shares Outstanding (Weighted Average) rose 98.02% to $40.0 million in Q4 2024 from the same period last year, while for Sep 2024 it was $38.6 million, marking a year-over-year increase of 92.40%. This contributed to the annual value of $40.0 million for FY2024, which is 98.02% up from last year.
  • According to the latest figures from Q4 2024, Solid Biosciences' Shares Outstanding (Weighted Average) is $40.0 million, which was up 3.52% from $38.6 million recorded in Q3 2024.
  • Solid Biosciences' 5-year Shares Outstanding (Weighted Average) high stood at $40.0 million for Q4 2024, and its period low was $3.1 million during Q1 2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $19.8 million (2023), whereas its average is $22.0 million.
  • Data for Solid Biosciences' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 167.79% (in 2023) over the last 5 years.
  • Over the past 5 years, Solid Biosciences' Shares Outstanding (Weighted Average) (Quarterly) stood at $4.0 million in 2020, then skyrocketed by 82.46% to $7.4 million in 2021, then rose by 2.47% to $7.5 million in 2022, then skyrocketed by 167.79% to $20.2 million in 2023, then soared by 98.02% to $40.0 million in 2024.
  • Its last three reported values are $40.0 million in Q4 2024, $38.6 million for Q3 2024, and $38.4 million during Q2 2024.